Coare Biotechnology, Inc.

Oklahoma City, OK 73104

SBIR Award Summary

Total Number of Awards 6
Total Value of Awards $2.82MM
First Award Date 07/01/13
Most Recent Award Date 07/01/17

Key Personnel

Last Name Name Awards Contact
Pantazis Panayotis Pantazis 2
SCHLOSSER MICHAEL J SCHLOSSER 3
SUREBAN SRIPATHI M SUREBAN 1

6 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-269
Budget: 07/01/17 - 06/30/18

Abstract: Pancreatic ductal adenocarcinoma (PDAC) is a devastating cancer with an extremely low 5-year survival rate even for those who are diagnosed early. Novel research suggests that this may be the result of metastatic dissemination preceding or concurrent to the development of the primary tumor. Epithelial- mesenchymal transition (EMT) is o...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-269
Budget: 07/22/16 - 06/30/17

Abstract: Pancreatic ductal adenocarcinoma (PDAC) is a devastating cancer with an extremely low 5-yearsurvival rate even for those who are diagnosed early. Novel research suggests that this may be the result ofmetastatic dissemination preceding or concurrent to the development of the primary tumor. Epithelial-mesenchymal transition (EMT) is one ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 04/07/15 - 12/31/15

DESCRIPTION (provided by applicant): Colorectal cancer (CRC) is the third leading cause of cancer-related death in the U.S. Although advances in CRC screening, surgical therapies and medical management have improved clinical outcomes, there still is a major need to develop better medical therapies for CRC, particularly among those with advanced...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 04/01/15 - 12/31/15

DESCRIPTION (provided by applicant): Pancreatic ductal adenocarcinoma (PDAC) is one of the most devastating human cancers. It is the fourth leading cause of cancer-related deaths in the U.S., with a 5% 5-year survival rate. Despite FDA- approved therapeutic regimens and advances in medical and surgical care, no significant impact on PDAC patien...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 07/01/13 - 02/28/14

DESCRIPTION (provided by applicant): Pancreatic ductal adenocarcinoma (PDAC) is a solid tumor and is the fourth leading cause of cancer-related death in the U.S. The 5-year survival rate of its victims is <5%. There is increasing evidence that most solid tumors have a subpopulation of tumor-initiating cells termed "cancer stem cells" (CSCs). The...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 07/01/13 - 02/28/15

DESCRIPTION (provided by applicant): Pancreatic ductal adenocarcinoma (PDAC) is a solid tumor and is the fourth leading cause of cancer-related death in the U.S. The 5-year survival rate of its victims is <5%. There is increasing evidence that most solid tumors have a subpopulation of tumor-initiating cells termed "cancer stem cells" (CSCs). The...